Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
Hilma J. van der Horst(Amsterdam University Medical Centers), Martine E.D. Chamuleau(Hovon), Inger S. Nijhof(St. Antonius Ziekenhuis), Tuna Mutis(Amsterdam University Medical Centers)
Cited by 72
Related Papers
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
|Blood|2016|377
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
|The Lancet|2021|337
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
|Leukemia|2015|266